Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ikena Oncology, Inc. SEC filings document the former IKNA oncology issuer, its clinical-development disclosures, and its later corporate transition under the name neBio, Inc. The filings include material-event reports, material agreements, shareholder voting matters, capital-structure disclosures, operating and financial results, and risk and clinical-regulatory updates.
Recent Form 8-K disclosures also record governance and reporting matters, including an independent auditor change, equity inducement plan disclosures, compensation-plan documentation, and registered common stock identified under the IMA symbol on The Nasdaq Capital Market.
Form 4 – ImageneBio, Inc. (ticker IKNA)
Chief Financial Officer Jotin Marango disclosed merger-related equity adjustments tied to the 25 Jul 2025 closing of ImageneBio’s combination with Inmagene Biopharmaceuticals (formerly Ikena Oncology). On 28 Jul 2025 the CFO received 15,776 common shares (code A) issued in exchange for former Ikena options. To cover withholding taxes, 4,630 shares were automatically surrendered at $17.16 per share (code F), leaving a direct holding of 11,146 shares.
All legacy Ikena stock options were cancelled (code D): 181,000; 105,000; and 397,199 options, totalling 683,199 contracts. Following the transactions Marango holds no derivative securities.
The filing reflects mandatory conversion mechanics of the merger rather than discretionary trading, so its informational value is limited. Nonetheless, the CFO now has an equity stake in the combined company, aligning interests with shareholders.
Amendment No. 1 to Schedule 13D shows that BML Investment Partners, L.P. and its managing member, Braden M. Leonard, have materially reduced their position in Ikena Oncology (IKNA).
- Open-market sales between 16-22 Jul 2025 totalled 1,459,110 shares at $1.20-$1.30 per share.
- Current ownership: BML Investment Partners 215,832 shares; Leonard 5,000 shares; aggregate 220,832 shares.
- The cover page lists the stake as 1.9 % of outstanding shares; Item 5 cites 8.35 %, signalling an internal discrepancy.
The filing states the shares were acquired for investment purposes, the group is now below the 5 % reporting threshold, and it has no present plans to influence corporate actions. Future trades may occur depending on market conditions. No contracts or arrangements with other parties were disclosed.
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) has filed an 8-K to confirm that on 25 Jul 2025 it closed the previously announced merger with Cayman-based Inmagene Biopharmaceuticals. Two wholly owned Cayman merger subsidiaries were used to combine Inmagene into the Delaware parent, leaving Inmagene as a wholly owned subsidiary.
Immediately after closing, the registrant changed its corporate name to “ImageneBio, Inc.” and updated its Nasdaq listing to the new ticker IMA. The company furnished, under Item 7.01 (Reg FD), a press release (Exhibit 99.1) announcing completion of the transaction; the release is incorporated by reference but not deemed “filed.” No consideration details, pro-forma financials or other quantitative information are provided in this report.